Vimarsana
Biggest News Aggregation in the World

Page 7 - Chronic Sinusitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chronic Sinusitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chronic Sinusitis Today - Breaking & Trending Today

Optinose Reports First Quarter 2021 Financial Results and Operational Updates - Vimarsana News

Optinose Reports First Quarter 2021 Financial Results and Operational Updates

Published: May 05, 2021 Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- OptiNose AS (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2021, and provided operational updates. “XHANCE net revenues increased 55% in the first q...

Growth Opportunities in the United States Drug Eluting Sinus Stent Market to 2025, Featuring Intersect ENT, Inc., Johnson & Johnson, Medtronic plc and Stryker Corporation - Vimarsana News

Growth Opportunities in the United States Drug Eluting Sinus Stent Market to 2025, Featuring Intersect ENT, Inc., Johnson & Johnson, Medtronic plc and Stryker Corporation

Share this article Share this article ResearchAndMarkets.com's offering. The US drug eluting sinus stent (DESS) market has increased significantly during the years 2018-2020, and projections are made that the market would rise in the next four years i.e. 2021-2025 tremendously. The drug eluting sinus stent (DESS) market is expected to increase due to surging healthcare expenditure, increasing prevalence of sinus related disorders, growing treatment in physician's office, limitations of FESS, favorable government initiatives for promoting the use of sinus stents, etc. Yet the market faces some...

Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER - Vimarsana News

Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER

Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER Specialty Care sales grew 18.3%, driven by strong Dupixent performance (+54.2% to €982 million). Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. General Medicines declined 7.5%, reflecting lower U.S. Diabetes sales, COVID environment and portfolio streamlining. CHC down 3.0% due to decreased sales of Cough & Cold related portfolio in Europe partially offset by Digestive Health brands. Leveraged business EPS as the result of prioritization within R&D and...

Detailed text transcripts for TV channel - CNN - 20171207:09:57:00 - Vimarsana News

Detailed text transcripts for TV channel - CNN - 20171207:09:57:00

Mockery. back then, theories ranged from allergies to chronic sinusitis. he has an zbiet. but now sniffle gate. paused about 11 minutes into the speech. the president blew a blessing. trump's tdentures are trying to escape his mouth. he's not known to wear dentures, also dry mouth he experienced. >> the core principals -- that time he had to reach for a bottle of water. a white house official would say only the president is perfectly healthy. the slurring gave the daily show a memorable ending for its trump's best words of 2017